
In this closing segment, faculty distill the practical philosophy that runs through the program: a center-based start with a deliberate, clearly communicated transition remains the right approach for most patients.

In this closing segment, faculty distill the practical philosophy that runs through the program: a center-based start with a deliberate, clearly communicated transition remains the right approach for most patients.

This segment compares the practical experience of delivering therapy across the center, local oncology, and home, and considers which patients are best suited to each.

This segment examines the burdens that persist even within a well-designed transition pathway.

This segment explores who owns each part of the transition and how teams keep patients safe once care moves closer to home.

This segment centers on a distinction faculty return to throughout: transitioning care is not transferring management.

This segment addresses the discomfort of moving infusion care off the trial model, where axatilimab was delivered at academic centers.

This segment walks through the practical mechanics of delivering infusion-based therapy in chronic GVHD, using axatilimab as the model.

This segment brings the approved therapies side by side and asks what actually drives treatment selection.

This segment offers a focused look at axatilimab, the first and only CSF1R-directed monoclonal antibody approved for chronic GVHD.

ROCKSTAR data and real-world experience position belimumab as a convenient, well-tolerated option for steroid-refractory chronic GVHD, while ibrutinib use declines.

Explore 2026 steroid-refractory chronic GVHD care: four FDA-approved drugs, key trial results, and how ECP fits into real-world treatment selection.

Explore 2026 options for steroid-refractory chronic GVHD: four FDA-approved agents, key trial evidence, and where ECP fits in care.

Experts detail how steroid-refractory chronic GVHD care now uses targeted therapies and personalized choices, weighing organs, side effects, and infusion logistics.